NASDAQ:ORGS

Orgenesis Stock Insider Trading

Healthcare > Biotechnology

Buy ORGS

*Your capital is at risk

$0.590

+0.0950 (+19.19%)

At Close: Jun 03, 2026

Orgenesis Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 98.49. In total, the insiders bought 4.47M and sold 60K ORGS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	98.49
● Buy	4.47M shares
● Sell	60K shares
94% Buy Activity Moderate Negative Correlation
Buy Signal High Confidence Apr 06, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 98.49. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (94% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 05, 2025 Buy	Common Stock	Malik Ariel 10 Percent Owner	10% Owner	0 Value: $0
Mar 05, 2025 Buy	Common Stock	Malik Ariel 10 Percent Owner	10% Owner	0 Value: $0
Dec 12, 2024 Buy	Stock Option A-Award	Adler Yaron Director	Director	1 750 Value: $2K
Dec 12, 2024 Buy	Stock Option A-Award	Pelavin Adam Director	Director	1 250 Value: $1K
Dec 12, 2024 Buy	Stock Option A-Award	Pelavin Adam Director	Director	625 Value: $613
Dec 12, 2024 Buy	Stock Option A-Award	Nanda Ashish Director	Director	1 835 Value: $2K
Dec 12, 2024 Buy	Stock Option A-Award	Nagaraj Santhosh Director	Director	1 250 Value: $1K
Dec 12, 2024 Buy	Stock Option A-Award	Nagaraj Santhosh Director	Director	625 Value: $613
Dec 12, 2024 Buy	Stock Option A-Award	Vider Itzhak Director	Director	1 500 Value: $1K
Dec 12, 2024 Buy	Stock Option A-Award	Bhalaji Jagannathan Director	Director	1 250 Value: $1K
Dec 12, 2024 Buy	Stock Option A-Award	Bhalaji Jagannathan Director	Director	625 Value: $613
Dec 12, 2024 Buy	Stock Option A-Award	Bhalaji Jagannathan Director	Director	625 Value: $613
Dec 12, 2024 Buy	Stock Option A-Award	Bhalaji Jagannathan Director	Director	1 250 Value: $1K
Dec 12, 2024 Buy	Stock Option A-Award	Vider Itzhak Director	Director	1 500 Value: $1K
Dec 12, 2024 Buy	Stock Option A-Award	Nagaraj Santhosh Director	Director	625 Value: $613
Dec 12, 2024 Buy	Stock Option A-Award	Nagaraj Santhosh Director	Director	1 250 Value: $1K
Dec 12, 2024 Buy	Stock Option A-Award	Nanda Ashish Director	Director	1 835 Value: $2K
Dec 12, 2024 Buy	Stock Option A-Award	Pelavin Adam Director	Director	625 Value: $613
Dec 12, 2024 Buy	Stock Option A-Award	Pelavin Adam Director	Director	1 250 Value: $1K
Dec 12, 2024 Buy	Stock Option A-Award	Adler Yaron Director	Director	1 750 Value: $2K
Nov 04, 2024 Buy	Warrant (right to buy) A-Award	Safier Jacob 10 Percent Owner	10% Owner	242 718 Value: $250.0K
Nov 04, 2024 Buy	Warrant (right to buy) A-Award	Safier Jacob 10 Percent Owner	10% Owner	242 718 Value: $250.0K
Oct 28, 2024 Buy	Common Stock J-Other	Nagaraj Santhosh	Director	0 Value: $0
Oct 28, 2024 Buy	Common Stock J-Other	Bhalaji Jagannathan	Director	0 Value: $0
Oct 28, 2024 Buy	Common Stock J-Other	Pelavin Adam	Director	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ORGENESIS INC.

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing ...

Read Full Profile Here